MedTrace Logo

Lead-212 PSV359 Therapy for Patients With Solid Tumors

NCT06710756 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2026-04-30

No results posted yet for this study

Summary

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Conditions

Interventions

DRUG

[203Pb]Pb-PSV359

\[203Pb\]Pb-PSV359 is administered by intravenous bolus injection for single-photon emission computed tomography imaging.

DRUG

[212Pb]Pb-PSV359

\[212Pb\]Pb-PSV359 is administered by intravenous infusion for treatment of FAP expressing cancers.

Sponsors & Collaborators

  • Perspective Therapeutics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2028-01-31
Completion
2032-05-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06710756 on ClinicalTrials.gov